

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 16th July 2025

FOI Ref No 29562

Requested Information:

1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:
 - Atezolizumab (Tecentriq)
 - Avelumab (Bavencio)
 - Carboplatin single agent or in any other combination
 - Carboplatin with Gemcitabine
 - Carboplatin with Gemcitabine + Avelumab (Bavencio)
 - Carboplatin with Paclitaxel
 - Cisplatin single agent or in any other combination
 - Cisplatin with Gemcitabine
 - Cisplatin with Gemcitabine + Nivolumab (Opdivo)
 - Cisplatin with Gemcitabine + Avelumab (Bavencio)
 - Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)
 - Nivolumab (Opdivo)
 - Pembrolizumab (Keytruda)
 - Other active systemic anti-cancer therapy
 - Palliative care only
 - Erdafitinib
2. How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies:
 - Carboplatin single agent or in any other combination
 - Carboplatin with Gemcitabine
 - Carboplatin with Gemcitabine + Avelumab (Bavencio)
 - Carboplatin with Paclitaxel
 - Cisplatin single agent or in any other combination
 - Cisplatin with Gemcitabine
 - Cisplatin with Gemcitabine + Avelumab (Bavencio)
3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Response:

1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:
 - Atezolizumab (Tecentriq) **2**
 - Avelumab (Bavencio) **8 (one within clinical trial)**
 - Carboplatin single agent or in any other combination **0**
 - Carboplatin with Gemcitabine **2**
 - Carboplatin with Gemcitabine + Avelumab (Bavencio) **0**
 - Carboplatin with Paclitaxel **0**
 - Cisplatin single agent or in any other combination **0**
 - Cisplatin with Gemcitabine **3**
 - Cisplatin with Gemcitabine + Nivolumab (Opdivo) **0**
 - Cisplatin with Gemcitabine + Avelumab (Bavencio) **0**
 - Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) **1 (private patient)**
 - Nivolumab (Opdivo) **0**
 - Pembrolizumab (Keytruda) **0**
 - Other active systemic anti-cancer therapy Carbogen + radiotherapy – **3**; mitomycin/fluorouracil + radiotherapy – **1**; paclitaxel - **1**
 - Palliative care only **0**
 - Erdafitinib **0**
2. How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies:
 - Carboplatin single agent or in any other combination **0**
 - Carboplatin with Gemcitabine **0**
 - Carboplatin with Gemcitabine + Avelumab (Bavencio) **0**
 - Carboplatin with Paclitaxel **0**
 - Cisplatin single agent or in any other combination **0**
 - Cisplatin with Gemcitabine **1**
 - Cisplatin with Gemcitabine + Avelumab (Bavencio) **0**
3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
 - **Javelin Study – 1 current patient**
 - **Please see appendix one**

Attachment(s):

Appendix one – FOI Ref 29562 Urothelial Cancer Clinical Trials

Date Response sent: 7th August 2025